Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals With Obesity and NAFLD
Launched by CHINA NATIONAL CENTER FOR CARDIOVASCULAR DISEASES · Dec 4, 2022
Trial Information
Current as of January 14, 2025
Unknown status
Keywords
ClinConnect Summary
The trial aims to evaluate the efficacy and safety of berberine treatment for obesity and NAFLD. Potential eligible patients will be recruited from 10-20 medical centers in China. After a 4-week run-in period with berberine, all the eligible participants will be randomized (1:1) to berberine 1.0 g per day plus lifestyle intervention (Arm A) or placebo plus lifestyle intervention (Arm B). The participants will be asked to attend the visit at least once every 2 months, and be followed up for 6 months.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants aged ≥18 years
- • Participants with obesity (i.e., BMI ≥ 28 kg/m2) and abdominal obesity (i.e., waist circumference ≥85 cm in female or waist circumference ≥90 cm in male)
- • Participants with NAFLD diagnosed by ultrasound, computed tomography or magnetic resonance imaging
- Exclusion Criteria:
- • Patients with established coronary heart disease, stroke, or peripheral arterial disease
- • Patients diagnosed with diabetes or taking oral glucose-lowering drugs
- • Patients with severely uncontrolled hypertension (i.e., SBP≥180mmHg and/or DBP ≥110mmHg)
- • Excess alcohol consumption (i.e., alcohol ≥ 20 g/day in female or alcohol ≥ 30 g/day in male)
- • Other causes of fatty liver disease, including alcohol or drug abuse, hepatitis B or C, autoimmune, hepatolenticular degeneration, total parenteral nutrition, inflammatory bowel disease, celiac disease, hypothyroidism, Cushing syndrome, β -lipoprotein deficiency, lipid atrophy diabetes, Mauriac syndrome, etc.
- • Patients with thyroid disease, including hyperthyroidism or hypothyroidism
- • Patients with cardiac insufficiency
- • ALT or AST ≥ 3 times upper limit of normal, liver cirrhosis or hepatic insufficiency
- • Patients with renal insufficiency: estimated glomerular filtration rate (eGFR) \< 60 ml/(min×1.73m2)
- • Patients who had weight loss surgery, or are currently taking drugs for weight loss, or plan to have weight loss surgery or drugs in the following 6 months
- • Patients diagnosed with glucose-6-phosphate dehydrogenase (G6PD) deficiency
- • Taking berberine or drug containing berberine in the past 1 month
- • Any adverse reaction to berberine
- • Severe constipation, diarrhea, and/or severe chronic intestinal diseases (e.g., ulcerative colitis, Crohn's disease, irritable bowel syndrome, etc.)
- • Patients who had to use long-term or intermittent corticosteroids, immunosuppressants, antibiotics, or other drugs that affect inflammatory biomarkers
- • Women who are pregnant or breastfeeding, or those who plan to be pregnant during the trial
- • Patients with malignant tumors
- • Patients with mental disorders, cognitive disorders, and/or other serious diseases
- • Those who participated or have been participating other trials during the last 3 months
- • Any other conditions that may hinder the compliance to the study intervention or follow-up visit
Trial Officials
Jing Li, PhD
Principal Investigator
National Center for Cardiovascular Diseases
Haibo Zhang, MD
Principal Investigator
National Center for Cardiovascular Diseases
About China National Center For Cardiovascular Diseases
The China National Center for Cardiovascular Diseases (NCCD) is a leading research and clinical trial sponsor dedicated to advancing cardiovascular health in China and globally. As a prominent institution, NCCD focuses on innovative research, clinical management, and education in cardiovascular medicine. The center plays a crucial role in conducting rigorous clinical trials aimed at developing new therapies and improving patient outcomes for cardiovascular diseases. Through collaboration with national and international partners, NCCD is committed to enhancing the understanding of cardiovascular conditions and translating research findings into practical applications for improved healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials